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Letters to the EditorNeuroinﬂammation in HCV-infection – Peril or protection?To the Editor:
We have read with interest the article by Byrnes et al. [1], who
prospectively evaluated the effect of HCV clearance with pegylat-
ed interferon/ribavirin (PegIFN/RBV) therapy on cerebral metab-
olism as well as cognitive function in 15 non-cirrhotic HCV
positive patients.
In their study, cerebral metabolites were measured with 1H
magnetic resonance spectroscopy (MRS) before, during, and
12 weeks after treatment, and neurocognitive dysfunction was
assessed by a psychometric test battery. In contrast to non-
responders or relapsers (NR/R; n = 5) patients with sustained
viral response (SVR; n = 8) showed a signiﬁcant reduction of the
choline/creatine and the myoinositol/creatine ratio in the basal
ganglia as well as improvement in verbal learning, memory and
visuo-spatial memory. Consequently, the authors concluded that
SVR was associated with a decrease of neuroinﬂammation and an
improvement of cognitive function. Indeed, this ﬁnding of
improvement with viral clearance ﬁts the expectation that viral
clearance should improve HCV-associated cognitive impairment.
However, a note of caution might be worthwhile.mparison of mean brain metabolite levels and psychometric results for
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Journal of Hepatology 2We recently found MRS markers of neuroinﬂammation to be
increased in HCV patients with only mild neuropsychiatric
symptoms in contrast to those with severe symptoms, suggest-
ing a neuroprotective effect of the inﬂammatory response [2].
Thus, our ﬁndings are in contrast to the conclusion drawn by
Byrnes et al., who hypothesize that their MRI results reﬂected
reduced neuroinﬂammation as a consequence of HCV eradica-
tion and that reduced neuroinﬂammation caused the improve-
ment of the psychometric test results observed in their patient
group.
Stimulated by the paper of Byrnes et al. [1], we had a second
look at our data and performed additional analyses. Firstly, we
compared MRS data and psychometric test results of the 53
PCR positive patients described before [2], to data of 9 PCR neg-
ative patients who had undergone the same study protocol. Sec-
ondly, we compared the non-responders in our patient group
(n = 18) to patients with SVR after PegIFN/RBV therapy (n = 6).
Chosen regions of interest were basal ganglia (BG), parietal white
matter (PWM), occipital cortex (OC) and pons. Spectra were ana-
lysed using LC model as described in [2].PCR+ vs. PCR patients and for sustained responders vs. non-responders.
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signiﬁcant group differences in these regions.
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In contrast, the PCR negative patients showed signiﬁcantly lower
choline (Cho), myoinositol (mI) and creatine (Cr) levels in PWM,
and signiﬁcantly decreased creatine and N-acetylaspartate (NAA)
levels in OC compared to the PCR positive patients, while they
tended to score worse in the psychometric tests, especially the
Fatigue Impact Scale and the memory for words (Table 1). Non-
responders and SVR patients did not signiﬁcantly differ except
for a signiﬁcantly higher NAA level in the latter in PWM. Our
new observations (summarized in Table 1) again do not support
the hypothesis suggested by Byrnes et al. that SVR is accompa-
nied by a decrease in neuroinﬂammation thereby leading to an
improvement in cognition.
We believe that different factors might have biased the work
of Byrnes et al. If their concept was true, shouldn’t patients with
NR/R have shown a lack of improvement? However, both groups
in their study (patients with SVR and NR/R patients) showed an
improvement of psychometric test results with repetitive testing.
In addition, the two patient groups are far too small with 7 and 4
subjects, respectively, for analysing treatment effects on the test
results during follow-up. Conﬂicting results from different stud-
ies [2,3] suggest that more efforts and research resources need
to be allocated to address the true impact of HCV eradication
on neuropsychiatric symptoms in patients with hepatitis C. In
the future, interferon associated with non-interferon associated
viral clearance and potential differences on mental performance
should be compared.
Concerning the MRS results, we would like to address addi-
tional caution. Signiﬁcant metabolite changes have been
observed in the basal ganglia, only by Byrnes et al. [1]. As shown
in their Fig. 1, the voxel of basal ganglia they used, contains a
component of the anterior limb of the internal capsule and sur-
rounding white matter (WM). It is known that the metabolite dis-
tribution in WM and gray matter (GM) is quite different [4].
Therefore, a voxel placement containing such a partial volume
effect will reduce the reproducibility of the results by a study
with follow-ups. In addition, it has to be considered that the
metabolite Cr, which has been used by the authors as internal cal-
ibration factor, is a glial marker and thus cannot be considered as
a control metabolite – especially not in a study dealing with
neuroinﬂammation.922 Journal of Hepatology 20Conﬂict of interest
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